• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

游离血浆药物水平和P-糖蛋白转运数据在预测中枢神经系统暴露中的应用。

Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.

作者信息

He H, Lyons K A, Shen X, Yao Z, Bleasby K, Chan G, Hafey M, Li X, Xu S, Salituro G M, Cohen L H, Tang W

机构信息

Department of Drug Metabolism and Pharmacokinetics, Merck Research Laboratories, Rahway, NJ 07065-0900, USA.

出版信息

Xenobiotica. 2009 Sep;39(9):687-93. doi: 10.1080/00498250903015402.

DOI:10.1080/00498250903015402
PMID:19569734
Abstract
  1. Drug concentrations in cerebrospinal fluid have been assumed to be a natural surrogate for total drug exposures in the central nervous system. The present communication reports a data set from a study of 30 compounds in mice. An attempt was made to correlate cerebrospinal fluid and unbound plasma drug concentrations via incorporation of in vitro P-glycoprotein (Pgp)-mediated transport data. 2. Pgp-deficient (Pgp -/-) and wild-type mice were dosed with compounds of interest by oral gavage (orally) at 5 mg kg(-1). Plasma and cerebrospinal fluid samples were collected at 1 h post-dosing, and analysed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) for drug concentrations. Mouse and human Pgp-mediated transport were evaluated in vitro by a bi-directional (B to A and A to B) transport assay using LLC-PK1 cells expressing mouse (mdr1a) and human (MDR1) forms of Pgp, respectively. 3. Compounds with B to A/A to B transport ratios < 2 were defined as non-substrates of Pgp, whereas those exhibiting B to A/A to B transport ratios > or =2 were considered Pgp substrates. Plasma protein binding was also determined in vitro via equilibrium dialysis. Of the 30 compounds, 13 were identified to be mouse Pgp substrates, all of which were also human Pgp substrates, demonstrating a good agreement between mouse and human data. 4. In Pgp wild-type mice, the unbound plasma and cerebrospinal fluid concentrations of the non-Pgp substrates correlated well, with a regression slope of approximately 1.0. A similar relationship existed for Pgp substrates in Pgp -/- mice. On the other hand, an improved correlation of cerebrospinal fluid and systemic exposures of the Pgp substrates in Pgp wild-type mice was observed when the unbound plasma concentrations were normalized to the corresponding B to A/A to B transport ratios. 5. These results reinforce the premise that a combined use of unbound plasma drug concentrations and in vitro Pgp transport data may be of value for the estimation of central nervous system exposures.
摘要
  1. 脑脊液中的药物浓度一直被视为中枢神经系统中药物总暴露量的天然替代指标。本报告呈现了一项针对小鼠体内30种化合物的研究数据集。研究尝试通过纳入体外P-糖蛋白(Pgp)介导的转运数据,来关联脑脊液和非结合血浆药物浓度。2. 对Pgp基因缺陷(Pgp -/-)小鼠和野生型小鼠经口灌胃给予5 mg kg(-1)的感兴趣化合物。给药后1小时采集血浆和脑脊液样本,并用液相色谱-串联质谱法(LC-MS/MS)分析药物浓度。分别使用表达小鼠(mdr1a)和人类(MDR1)形式Pgp的LLC-PK1细胞,通过双向(B到A和A到B)转运试验在体外评估小鼠和人类Pgp介导的转运。3. B到A/A到B转运比<2的化合物被定义为Pgp的非底物,而那些B到A/A到B转运比>或 =2的化合物则被视为Pgp底物。还通过平衡透析在体外测定血浆蛋白结合率。在这30种化合物中,有13种被鉴定为小鼠Pgp底物,所有这些化合物也都是人类Pgp底物,表明小鼠和人类数据之间具有良好的一致性。4. 在Pgp野生型小鼠中,非Pgp底物的非结合血浆和脑脊液浓度相关性良好,回归斜率约为1.0。Pgp -/-小鼠中的Pgp底物也存在类似关系。另一方面,当将非结合血浆浓度根据相应的B到A/A到B转运比进行归一化时,在Pgp野生型小鼠中观察到脑脊液与Pgp底物全身暴露量之间的相关性得到改善。5. 这些结果强化了这样一个前提,即联合使用非结合血浆药物浓度和体外Pgp转运数据可能对估计中枢神经系统暴露量有价值。

相似文献

1
Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.游离血浆药物水平和P-糖蛋白转运数据在预测中枢神经系统暴露中的应用。
Xenobiotica. 2009 Sep;39(9):687-93. doi: 10.1080/00498250903015402.
2
Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys.P-糖蛋白介导的外排在恒河猴脑脊液浓度中的作用。
Biochem Pharmacol. 2009 Sep 15;78(6):642-7. doi: 10.1016/j.bcp.2009.05.026. Epub 2009 May 27.
3
In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.体外P-糖蛋白测定法用于预测P-糖蛋白在中枢神经系统中与药物的体内相互作用。
Drug Metab Dispos. 2008 Feb;36(2):268-75. doi: 10.1124/dmd.107.017434. Epub 2007 Oct 25.
4
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.细胞色素P450 3A抑制剂与P-糖蛋白的相互作用。
J Pharmacol Exp Ther. 2002 Oct;303(1):323-32. doi: 10.1124/jpet.102.037549.
5
Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio.P-糖蛋白介导的外排对脑脊液/血浆浓度比的影响。
Drug Metab Dispos. 2003 Oct;31(10):1251-4. doi: 10.1124/dmd.31.10.1251.
6
Several major antiepileptic drugs are substrates for human P-glycoprotein.几种主要的抗癫痫药物是人类P-糖蛋白的底物。
Neuropharmacology. 2008 Dec;55(8):1364-75. doi: 10.1016/j.neuropharm.2008.08.032. Epub 2008 Sep 11.
7
PK/PD assessment in CNS drug discovery: Prediction of CSF concentration in rodents for P-glycoprotein substrates and application to in vivo potency estimation.中枢神经系统药物发现中的 PK/PD 评估:对 P-糖蛋白底物的啮齿动物 CSF 浓度预测及其在体内效力估计中的应用。
Biochem Pharmacol. 2013 Jun 1;85(11):1684-99. doi: 10.1016/j.bcp.2013.02.021. Epub 2013 Feb 27.
8
Synthesis, molecular structure, and validation of metalloprobes for assessment of MDR1 P-glycoprotein-mediated functional transport.合成、分子结构和金属探针的验证用于评估多药耐药 1 型 P 糖蛋白介导的功能转运。
Dalton Trans. 2010 Jul 7;39(25):5842-50. doi: 10.1039/c002361b. Epub 2010 May 27.
9
Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies.泊洛尼克P85增强地高辛向脑内的递送:体外和体内研究
J Pharmacol Exp Ther. 2001 Feb;296(2):551-7.
10
Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.一种用于评估涉及P-糖蛋白的潜在临床药物相互作用的体外技术的开发、验证及应用
Eur J Pharm Sci. 2006 Apr;27(5):543-54. doi: 10.1016/j.ejps.2005.11.011. Epub 2006 Jan 10.

引用本文的文献

1
Unbound Brain-to-Plasma Partition Coefficient, K-a Game Changing Parameter for CNS Drug Discovery and Development.未结合脑-血浆分配系数:改变中枢神经系统药物研发游戏规则的参数。
Pharm Res. 2022 Jul;39(7):1321-1341. doi: 10.1007/s11095-022-03246-6. Epub 2022 Apr 11.
2
The Exploration of Chirality for Improved Druggability within the Human Kinome.手性在人类激酶组中提高成药性的探索。
J Med Chem. 2020 Jan 23;63(2):441-469. doi: 10.1021/acs.jmedchem.9b00640. Epub 2019 Oct 9.
3
Construction of P-glycoprotein incorporated tethered lipid bilayer membranes.
包含P-糖蛋白的拴系脂质双分子层膜的构建。
Biochem Biophys Rep. 2015 Jun 4;2:115-122. doi: 10.1016/j.bbrep.2015.05.012. eCollection 2015 Jul.
4
Discovery and Optimization of a Novel Triazole Series of GPR142 Agonists for the Treatment of Type 2 Diabetes.用于治疗2型糖尿病的新型三唑类GPR142激动剂的发现与优化
ACS Med Chem Lett. 2016 Oct 12;7(12):1107-1111. doi: 10.1021/acsmedchemlett.6b00314. eCollection 2016 Dec 8.
5
Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.强效且选择性的IRAK4酰胺吡唑抑制剂,在啮齿动物炎症模型中具有疗效。
ACS Med Chem Lett. 2015 May 12;6(6):677-82. doi: 10.1021/acsmedchemlett.5b00106. eCollection 2015 Jun 11.
6
Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.强效、选择性促生长激素释放激素受体3拮抗剂MK-1421作为2型糖尿病开发候选药物的发现。
ACS Med Chem Lett. 2015 Mar 18;6(5):513-7. doi: 10.1021/ml500514w. eCollection 2015 May 14.
7
Design of prodrugs to enhance colonic absorption by increasing lipophilicity and blocking ionization.通过增加脂溶性和亲脂性和抑制离子化来增强结肠吸收的前药设计。
Pharmaceuticals (Basel). 2014 Feb 24;7(2):207-19. doi: 10.3390/ph7020207.